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Introduction: Chronic wounds are a major health-care issue, but research is limited by the complexity and heterogeneity
in terms of wound etiology as well as patient-related factors. A suitable animal model that replicates the situation in
humans is not available. Therefore, the aim of the present work is to present a standardized human wound model
and the data of a pilot study of topically applied progenitor cells in a sacral pressure sore.
Methods: Three patients underwent cell harvest from the iliac crest at the time of the initial debridement. Forty-eight
hours after bone marrow harvest and debridement, the CD34+ selected cell suspension was injected into the wound.
With the aid of a laser scanner, three-dimensional analyses of wound morphometry were performed until the defect
was reconstructed with a local flap 3 weeks after debridement.
Results: Decreases in volume to 60%± 6% of baseline on the sham side and to 52%± 3% of baseline on the cell side
were measured. Histologic work-up revealed no signs of metaplastic, dysplastic, or neoplastic proliferation/differentiation
after progenitor cell treatment. CD34+ cells were detected in the biopsies of day 0.
Conclusions: The pressure sore wound model allows investigation of the initial 3 weeks after cell-based therapy.
Objective outcome analysis in terms of wound volume and histology can be performed without, or with, minimal
additional morbidity, and the anatomy of the sacral area allows a control and study side in the same patient. Therefore,
this model can serve as a standard for wound-healing studies.
Trial registration: ClinicalTrials.gov NCT00535548.Introduction
Chronic wounds are an enormous burden for the patients
and their families, represent a major challenge for the
treating clinicians, and have a tremendous impact on
health-care costs. A considerable amount of research has
been dedicated to different types of wound dressings. The
impact of these modern dressing types on wound healing,
however, is frequently disappointing as their efficacy has
not been validated in late-stage clinical trials. This may be
related to the fact that single agents cannot interfere with
the complex interplay of wound healing.* Correspondence: reto.wettstein@usb.ch
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reproduction in any medium, provided the orRecent interest in the treatment of chronic wounds has
shifted from the type of dressing—with or without pharma-
ceutical agents and growth factors—to cell-based therapies.
Stem cell therapies, using hematopoietic stem cells for non-
hematopoietic indications as well as non-hematopoietic
stem cells for tissue repairs, have increased over the last
years for a broad series of indications [1]. Promising results
have been reported in the treatment of small series of mainly
chronic lower-extremity wounds with bone marrow-derived
stem cells [2-9]. The rationale behind the use of cell-based
therapies—besides the presence of macro- and microvascu-
lar disease leading to ischemia and hypoxia or hypergly-
cemia, infection, and inflammatory reactions and so on—is
the fact that cells in chronic wounds are phenotypically
altered or senescent or both [10,11]. Therefore, they have
a limited capacity to divide and are less responsive toral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ties of stem and progenitor cells that create a local environ-
ment conductive to wound healing are lacking.
One of the major problems in chronic wound research
is the heterogeneity of the patient population suffering
from chronic wounds in terms of ulcer etiology (that is,
traumatic, diabetic, venous, arterial, mixed, pressure, and
radiation-induced). In addition, ulcer size and localization
vary as patient comorbidities, overall health status, nutri-
tional status, and social environment do. On the other
hand, the combination of different treatment modalities,
the timing and mode of their application, and the pre- and
post-treatment wound care to obtain stable wound closure
without recurrence—the ultimate goal—differ in many
ways and render an objective analysis of any potential
benefit of a treatment strategy difficult, not to mention the
different sources and preparations of cells used in cell-
based therapies.
Another major issue in chronic wound research, besides
the heterogeneity of wound etiology and patient-related fac-
tors, is the lack of suitable animal models replicating chronic
wounds. Mimicking the complexity of chronic wounds in an
animal is currently not possible. This further underscores
the need for a standardized human wound model. To im-
prove these methodological limitations, a novel human
chronic wound model is presented that allows a standard-
ized, objective outcome analysis of the wound dimensions,
for histological work-up and ideally for a direct comparison
of two different treatment modalities in the same patient. In
this pilot study, the effect of topically applied hematopoietic-
derived progenitor cells on wound healing in a sacral pres-
sure sore wound model was evaluated.
Patients and methods
Patients
Complete para- or tetraplegic patients who were hos-
pitalized at the Swiss Paraplegic Center in Nottwil,
Switzerland, and who presented with a primary sacral
pressure sore grade III-IV (that is, without bone involve-
ment and signs of osteomyelitis) were prospectively
included in the study. Exclusion criteria were age of less
than 18 or more than 50 years and presence of HIV,
hepatitis B or C, active malignancy, malnutrition, dia-
betes mellitus, smoking, cardiopulmonary disease, per-
ipheral arterial vascular disease, or systemic diseases like
chronic polyarthritis, lupus, or scleroderma. Also, pa-
tients on steroids, chemotherapeutics, or oral anticoagu-
lants were excluded from the study. The protocol was
approved by the local institutional review board of the
Canton of Lucerne (#552). Written informed consent
was obtained from all patients included in the study and
included approval for publication of information about
themselves and fotodocumentation in this journal. Each
patient signed these forms of consent.Wound preparation
Wound debridement was performed in a standardized
en-bloc technique in the operation room under sterile
conditions. Hemostasis was achieved by cauterization and
application of warm compresses. For all operations, min-
imal anesthesia care was provided for patient monitoring.
No local or systemic anesthetics were necessary in this pa-
tient group. Wound dressings during the entire study
period were performed with moist gauzes (Ringer’s lactate)
twice a day. No disinfectant substances were used.
Cell harvest and progenitor cell isolation
At the time of wound debridement, bone marrow (100 mL)
was harvested from the posterior iliac crest by repetitive
punctures and aspirations. Cell count, CD34 count, viabil-
ity, and microbiologic cultures were performed at the stem
cell laboratory of the University Hospital of Basel. After
overnight storage, CD34 selection was performed with
magnetic beat-loaded antibodies with the CliniMACS cell
separation model CS2-CE/UL (Miltenyi Biotec, Bergisch
Gladbach, Germany). After selection, cell count, CD34 and
lymphocyte subclass counts, viability and sterility tests were
performed. Cells were once again stored overnight and then
concentrated.
Progenitor cell therapy
Forty-eight hours after bone marrow harvest and de-
bridement, the CD34+ selected stem cell suspension was
injected into the wound. One side of the wound was
treated by injection of the cell suspension, and the other
side served as control and was treated with an identical
volume of NaCl 0.9%. For injection, the wound was sub-
divided with a grid into small areas of 1 cm2 (Figure 1).
Fractionated injections were performed into the wound
bed as well as perifascially, subcutaneously, and subder-
mally at the borders of the wound.
Endpoints
Wound morphometry
Changes in wound diameter and defect volume were
assessed with a three-dimensional (3D) laser scanner (VI-
910 Non-contact 3D digitizer; Konica Minolta Inc., Tokyo,
Japan). The method has been described in detail elsewhere
[12,13]. Briefly, with the patient in the prone position, the
scanner was positioned parallel to the wound with a
custom-made carrier that essentially consists of a C-shaped
frame that permits the scanner to be positioned over the
bed, at a fixed distance from the pressure sore. The cap-
tured images were imported with the Geomagic studio 12
program (Geomagic Inc., Raleigh, NC, USA) and converted
into a single virtual 3D model for further analysis. Care was
taken that the patient was lying flat without any sheets or
pillows that may create an oblique incidence. With Free-
Form modeling plus and Phantom desktop software
Figure 1 Mapping of the pressure sore 48 hours after debridement with the planned injections sites for the stem cells on the left side.
(a) The stem cell solution is used on one side of the pressure sore, and a sham solution is used on the other side (at a distance of 1 cm in radius
around injection sites). The midline can easily be identified by orientation of anatomical landmarks (rima ani, spine, or the anus). For the sake of
clarity, the injection points on the control side are not included in the picture. (b) Injection of the progenitor cells.
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sure sore are marked. In this procedure, in contrast to other
plastic surgical procedures in which laser scanning can be
used (for example, breast volume changes), definition of the
borders is unequivocal in sacral pressure sores. Also, the
midline of the pressure sore can be easily defined by orien-
tation on the spine cranially and the rima ani caudally.
Since there is no undermining of the wound edges after the
debridement, no shadows occur. Two patches representing
the two sides of the defect were created. The surface of the
patches was adapted to the anatomic curvature of the
sacrum. The respective dimensions of the treated and un-
treated sides can then be calculated and were indicated in
absolute values.
Histology
For histological examination, two punch biopsies of 2 mm
in diameter were harvested at two sites on each side of the
wound on corresponding localizations at days 0 (day of
stem cell injection), 3, 5, 12, and 19 (that is, at the different
phases of wound healing). To avoid taking biopsies from
the same location twice, a clockwise rotation was per-
formed in predefined sectors. Biopsies were fixed in 4%
buffered formaldehyde and paraffin-embedded. The slides
(10 μm) were stained with hematoxylin-eosin, Giemsa,
and periodic acid-Schiff staining for analysis of signs of
metaplasia, dysplasia, or malignant transformation. For
identification of CD34+ cells, an immunohistochemical re-
action with intrahepatic leukocyte-4 (IHL-4) was per-
formed. No anesthesia was required for harvesting the
biopsies.
Study protocol
In keeping with the general treatment concept of pres-
sure sores at our institution, all wounds were debrided,
conditioned, and reconstructed after 21 days [14]. At the
initial debridement session, cells were harvested from
the posterior iliac crest. Forty-eight hours later, the cells
were injected into the wound. In all patients, the left sideof the pressure sore was treated with cells. Biopsies were
taken at the initial debridement and on days 0 (day of
stem cell application), 3, 5, 12, and 19 after cell applica-
tion. For scanning analysis, day 5 was considered the
baseline value in order to eliminate any potential con-
founding factors such as edema by surgical trauma and
local fluid irrigation. Flap coverage of the defect was per-
formed after re-debridement and the last endpoint
assessment. Clinical follow-up of 2 years after cell appli-
cation was chosen for clinical monitoring for any signs
of development of malignancy.
Results
Patients
Of a total of 35 patients presenting with sacral pressure
sores between January 2007 and December 2008, three
male patients met the restrictive inclusion criteria. The
ages of the patients were 40, 20, and 49 years. Exclusion
criteria were pressure sores of higher than grade IV in
11 cases, comorbidities in 10 cases, and absence of in-
formed consent in three cases, and three patients had
preserved sacral sensibility. Three patients were too
young, two patients presented with osteomyelitis, and
one had positive bacterial culture of the bone marrow
aspirate. The study was finished prematurely to widen
the inclusion criteria.
Cell injection
The total numbers of injected CD34+ cells were 25.5 ×
106 (patient 1: 4.2 mL), 18.3 × 106 (patient 2: 4.5 mL),
and 17.4 × 106 (patient 3: 3.8 mL). The values of injected
CD34+ cell count/cm2 of the treated wounds were 0.5 ×
106, 2.2 × 106, and 0.6 × 106 cells/cm2 for patients 1, 2,
and 3, respectively.
Histology
In total, 120 biopsies were examined at the Institute of
Pathology, University Hospital Basel, Switzerland. None
of the biopsies showed signs of metaplastic, dysplastic,
Table 1 Wound morphology data
Volume, cm3 Circumference, mm
Control side Stem cell side Control side Stem cell side
Patient 1 905 660 190 180
Patient 2 53 36 77 70
Patient 3 253 310 138 138
Absolute values as assessed by three-dimensional laser scanning at day 5 of
the volume of the pressure sore and the circumference.
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tor cell treatment. CD34+ stem cells were detected in
the biopsies of day 0 (day of application) (Figure 2).
From day 3 on, progenitor cell could not be identified
with certainty anymore.
Three-dimensional laser scans
The total volume and circumference of the treated and
untreated sides of the pressure sores at day 5 are sum-
marized in absolute values in Table 1. Within the 14
days from day 5 to day 19, there were decreases in vol-
ume to 60% ± 6% of baseline on the sham side and to
52% ± 3% of baseline on the progenitor cell side
(Figure 3). Changes in the circumference of the two
sides were less spectacular, with decreases to 86% ± 9%
and 82% ± 4% of baseline on the sham and progenitor
cell sides (Figure 4).
Follow-up
Healing after flap surgery was uneventful in the three
patients. During the regular follow-up examinations for
2 years post-operatively, no signs of malignancy were de-
tected by local clinical inspection and palpation.
Discussion
Basically, standard treatment for advanced pressure
sores in plegic patients consists of debridement, wound
conditioning, and pressure offload followed by defect
closure with local flap procedures [14]. The time for
wound bed preparation between debridement and defect
closure is usually about 3 weeks. This interval represents
a window for experimental investigations. Since most of
sacral pressure sores cross the midline—a landmark
which is easily identified and which can serve as an
orientation in the analysis of scanning—each patient,Figure 2 Biopsy at day one confirming the presence of CD34+
progenitor cells marked in brown (immunohistochemical
reaction with intrahepatic leukocyte-4 (IHL-4). Magnification 20×.respectively one of the two halves of the pressure sore
can serve as control. The midline represents an easily
identifiable landmark that permits to consistently divide
the sacral pressure sore in a left and right half, respect-
ively a control and treatment side. Another advantage of
the flat wound appearance is the accessibility for scans.
In flat wounds, compared with deep wounds, there are
fewer scan shadows, thus reducing the number of scans
needed to get the whole picture. In addition, it is routine
practice to excise the wound borders and ground before
flap closure, a manoeuver that provides local control
after application of test agents. During scanning and bi-
opsies, the patient remains in a comfortable prone pos-
ition, and this increases the patient’s compliance greatly,
reducing the biopsy process time and increasing the
quality of the scans by reducing body movement. An-
other advantage of this wound model is that intermedi-
ate biopsies can be harvested without significant
additional morbidity and without the need for anesthesia
(in complete para-/tetraplegic patients), which may posi-
tively influence the quality of the histologic work-up.
In the three patients included in this pilot study, the sin-
gle application of autologous, isolated, but unexpanded
hematopoietic stem cells seems to positively influence
granulation tissue formation and wound contraction as
assessed by 3D laser scanning, which showed about a 50%
reduction in the volume of the pressure sore on the
treated side versus a 40% reduction on the control side.Figure 3 Decrease in the volume of the wound on the control side
(dotted line) and the stem cell side (continuous line) normalized to
the values of day 5 (mean± standard deviation). D, day.
Figure 4 Laser scanning images of the same pressure sore. Image-processed scans of a treated pressure sore (a) after treatment and at
(b) 5 days, (c) 12 days, and (d) 19 days.
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sults cannot be analyzed statistically and the biological or
clinical benefit may be minimal at best; however, the aims
of study were to establish this pressure sore model and to
exclude any signs of malignancy after local application of
cells in these three patients who were observed for 3
weeks. The number of patients and the follow-up certainly
render any comment on safety and efficacy of this ap-
proach impossible. The strict inclusion criteria in this
safety study restricted the number of patients included
considerably. A reduction in ulcer size of more than 70%
when compared with 30% in control subjects was identi-
fied after 12 weeks; however, cells were administered sev-
eral times [8]. The interval for maximal action of a cell-
based therapy in a previous study has shown that no
changes occurred after 14 days, a time point at which min-
imal wound size was measured after a single cell applica-
tion [15]. Fibroblasts, which are attracted from the edge of
the wound or from the bone marrow, are stimulated by
macrophages and some differentiate into myofibroblasts
[16]. This effect might be accentuated by applying stem
cells into the wound and may partly explain the trend to-
ward increased wound contraction observed in the present
study. In the present study, the amount of wound volume
reduction by the formation of granulation tissue is less
relevant since defect closure was performed with a flap.
For most clinical cases, stimulation of granulation tissue
formation, increased wound contracture and epithelialisa-
tion would be the primary goals in order to shorten the
overall treatment period.
Different reports on cell-based chronic wound therapy
showed a positive influence on wound healing; however,
a precise and objective analysis of the effect of the ther-
apies used is difficult, and frequently there are no data
on wound contracture, development of granulation tis-
sue, or epithelialization [3,5,7,8,15,17-19]. Some of these
reports show complete healing of long-lasting chronic,
usually lower extremity, wounds. However, either mul-
tiple cell applications or combinations of cell therapy
and skin grafting procedures were used and led eventu-
ally to wound closure. Whereas stable wound closure is
the clinically important endpoint, the pathophysiological
mechanisms underlying the conversion from a chronicwound, with its derangements in the healing cascade, to
a healing wound need further investigation. The sacral
pressure sore model is ideal to analyze the initial period
of wound changes after cell application (that is, the con-
version from a non-healing to a healing wound); how-
ever, it has the obvious disadvantage that healing by
secondary intention would take a long time, potentially
yield unstable scar tissue at the site of pressure, and
therefore be unethical. In this pilot study, no attempt
was made to establish a dose dependency of the cell-
based therapy, and the patients received different
numbers of cells in total and per surface area treated.
Obviously, in a large-scale study, the number of cells
administered should be matched to the defect size.
In terms of safety, histological analysis did not reveal
any signs of malignant transformation in the present
study. This has been corroborated by different studies
using bone marrow-derived cells for the treatment of
chronic wounds, where no changes in inflammatory re-
actions or in differential blood count were observed or
changes in laboratory analysis occurred [8,15]. The long-
term clinical follow-up examinations did not show any
signs of cancerous masses in the area of treatment. Also,
adverse effects of the cell application have not been ob-
served in the present study or previously reported. Al-
though malignant transformation is an uncommon event
in the chronic wound environment [20], studies showed
that signaling pathways of healing skin wounds strongly
resemble those of malignant tumors [21]. Our results
showed that there is no sign of malignant transformation
during the observed period. Furthermore, the design of
the study reduces the potential risk of progenitor-cell in-
duced malignant tissue transformation by the fact that
the treated area is totally excised before surgical wound
closure.
Future studies with this model will allow researchers to
analyze the effect of cell preparation, selection, culture,
and storage and to identify the potential of cells from
other sources than bone marrow, which is a very well-
known origin of hematopoietic and non-hematopoietic
stem cells, including mesenchymal stem cells. Obviously,
proper characterization of cells is essential in order to ob-
tain consistent, reproducible results. Another essential
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between the number of cells applied and the decrease in
wound size observed has been reported [2]. Since the early
inflammatory phase is characterized by migration into the
wound of monocytes, which differentiate into macro-
phages [22] and since bone marrow-derived cells from the
hematopoietic stem cell lineage increase in number in der-
mal wounds and lead to increased wound contraction
[23], hematopoietic stem cells were used in this pilot
study. Also, the harvesting of bone marrow at the time of
the initial debridement did not require patient reposi-
tioning and was easy to perform. With increasing know-
ledge about stem cells, it seems as if different sources of
cells may be used and may result in similar effects.
One of the issues in stem cell-based wound therapy is
the mode of cell delivery [24]. In the present model, the
cells were injected directly into the wound borders and
wound ground, which was possible since pressure sores
with exposed bone were not included in the study. Direct
injection in the wound ground can be difficult in long-
standing leg ulcers with a thick layer of dense scar tissue,
which is sometimes accompanied by calcifications. Poten-
tial alternatives to direct injection are cell suspension in fi-
brin glue [2] and impregnation in a collagen matrix [6].
Obviously, the wound ground has to provide a critical
vascularization for the cells to survive. One of the reasons
to perform surgical debridement is to remove fibrin, nec-
rotic tissue, and scar tissue to obtain a bleeding wound
bed. This, however, is probably the major problem in
chronic leg ulcers, in which a through debridement fre-
quently exposes tendons or bone or a limited debridement
only leads to scarce bleeding points. In such a situation,
the injection of the cells is supposed to induce neoangio-
genesis, which ultimately leads to the formation of granu-
lation tissue. Cell-enhanced dressings are probably of little
value in such situations. Another limitation of this study is
that the patient served as his own control, and it cannot
be excluded that homing of the cells applied to the saline-
treated control occurred and had a positive influence on
this side as well.
Conclusions
The proper and safe use of progenitor cells, as well as
the ideal source and type of cells, is currently not
known. One of the reasons is the lack of a suitable
model to investigate the effects of cell-based therapies
on chronic wounds. The presented pressure sore wound
model allowed us to investigate the initial 3 weeks after
cell-based therapy and thereby to further elucidate the
underlying pathophysiologic mechanisms. Since object-
ive outcome analysis in terms of wound volume and
histology can be performed with no or minimal add-
itional morbidity, this model can serve as a standard
model for wound healing. In this pilot feasibility andsafety study, there was a trend toward increased granula-
tion tissue formation and wound contracture in the
three patients assessed.
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